Company Profile
GRI Bio Stock Price, News & Analysis
- Ticker:
- GRI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.55 USD (+1.31%)
Close
Last updated: August 6, 2026
3.56M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GRI closed up 1.31% at $1.55. No new same-company headline was identified in the current news window.
Company overview
Business overview
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Geographic Base and Sector Classification
GRI is a U.S.-listed biotech entry with a small-cap development profile. It sits in biotechnology rather than medtech or services.
Business Model Characteristics
The business depended on early scientific progress, platform credibility, and access to capital. Investors historically watched whether the company could focus its pipeline and keep programs alive.
Position Within the Biotechnology Landscape
GRI occupies the historical small-cap biotech bucket. It is the type of name where the market cared most about whether the science could survive the financing cycle.
Future catalysts
GRI Bio's catalyst setup now looks most tied to cough/shortness of breath, Commission, and the rest of its current pipeline. What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis.... That setup makes the next update more important than the headline financials themselves. The partnership angle also matters here, especially around (6) the inability of the Company to identify, in-license or acquire additional technology.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GRI Bio (GRI)?
GRI Bio (GRI) most recently closed at 1.55 USD, a +1.31% move versus the previous session.
What is the market cap of GRI Bio (GRI)?
GRI Bio currently has a market capitalization of 3.56M USD on BioPharmSignal.
What does GRI Bio do?
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
On which exchange is GRI stock listed?
GRI Bio (GRI) is associated with NASDAQ, United States, Biopharma.
What is GRI-0621?
What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis....
Which conditions is GRI Bio targeting with GRI-0621?
What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis....
How does GRI Bio describe recent progress with GRI-0621?
What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis....
What is BioRestorative?
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work.